Researchers implanted a long-term, intravenous therapy-delivery system consisting of internal pumps and catheters in 60 pulmonary arterial hypertension (PAH) patients, according to a clinical trial. The IV infusion system, developed by Medtronic, delivers Remodulin (treprostinil). The research team said the system should be easier to use than current therapy-delivery methods.
Patients who undergo splenectomy, or surgery to remove the spleen, increase their risk of pulmonary hypertension (PH), myocardial infarction and stroke. That’s the conclusion of a study, “Risk of cardiovascular events and pulmonary hypertension following splenectomy – a Danish population-based cohort study from 1996-2012,” that appeared in the journal Haematologica.
The average systemic sclerosis (SSc) patient burdened with pulmonary arterial hypertension (PAH) lives only four years after diagnosis, finds an Australian study, “Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension,” that appeared in the journal Arthritis Research & Therapy. PAH is a serious…
Whether a pulmonary arterial hypertension patient has scleroderma has no bearing on the outcome of their PAH after they receive a lung transplant, a study reports. Scleroderma, also known as systemic sclerosis, is a chronic autoimmune disease caused by abnormal production of connective tissue. It primarily affects the skin…
People with chronic thromboembolic pulmonary hypertension (CTEPH) are more likely to have a depressive temperament, finds a Japanese study, “Depressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension” that appeared in the Circulation Journal. CTEPH is a progressive disease characterized by increasing pulmonary vascular resistance. Although the underlying…
A live, online mini-concert starring Chloe Temtchine has drawn thousands of viewers while raising awareness about pulmonary hypertension (PH), a progressive, life-threatening disease. The Facebook Live concert, presented recently by the Pulmonary Hypertension Association (PHA), attracted 1,500 live attendees and served as the finale for PHA’s World PH Day, the culmination…
Reviva Pharmaceuticals has obtained $4.8 million in financing to keep developing its treatments for pulmonary arterial hypertension (PAH) and other diseases. The financing, in the form of a loan that can be converted to stock, will help Reviva continue preparing for new clinical trials of its lead therapy, RP5063, Dr. Laxminarayan Bhat said…
Compounds that increase the amount of blood flowing through heart vessels can benefit people with pulmonary hypertension (PH) and chronic left heart disease who have decreased blood-pumping ability, according to an analysis of several studies. The compounds are phosphodiesterase-5 (PDE5) inhibitors such as Revatio (sildenafil). They prevent an enzyme called…
Stem cells known as mesenchymal progenitor cells (MPCs) may contribute to the blood vessel anomalies causing pulmonary hypertension (PH), says a new study, “Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction,” that appeared in the Journal of Clinical Investigation. Vascular anomalies in the lung are…
Collecting tissue samples from vessels damaged by pulmonary hypertension (PH) can help scientists learn about molecular mechanisms that cause the disease, as well as which may help in its treatment, according to a new study. The study, “Assessment of microRNA and gene dysregulaton in pulmonary hypertension by…
Antiphospholipid antibodies (aPL) could signal that a lupus patient is at risk of developing pulmonary hypertension (PH) and related conditions, according to a study. Researchers called for additional studies that would lead to doctors using the antibodies’ presence in blood to screen such patients and develop early treatment strategies for…
The INOpulse portable oxygen provider widened blood vessels, lowered blood pressure and increased exercise capacity in pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to a study. Bellerophon Therapeutics, which developed the device, reported the results at the American Thoracic Society International Conference in Washington. It also discussed plans for…
Get regular updates to your inbox.